Odyssey Health, Inc. Preparing for a Phase II Pharmaceutical Concussion Treatment
Las Vegas, NV,
|
March 30, 2023 08:30 AM Eastern Daylight Time
McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on creating unique, life-enhancing medical products, is developing a novel neuropharmaceutical treatment for mild Traumatic Brain Injury (mTBI) also known as a concussion. Recently, the world’s leading research agency, the National Institutes of Health (NIH), acknowledged that Chronic Traumatic Encephalopathy (CTE) is caused by repetitive head trauma, not uncommon in the field of sports and in our military. Odyssey’s lead drug candidate, ONP-002, is designed for the acute setting using an intranasal neurosteroid that works to simultaneously reduce swelling, inflammation, and oxidative stress. Odyssey has completed a Phase I clinical trial and is now preparing for a Phase II study to determine the safety and efficacy of its drug.
The National Football League (NFL) announced an eighteen percent (18%) increase in concussions sustained in the 2022 season compared to 2021, potentially due to the increased sideline concussion protocols. On average the NFL conducts 1.6 sideline concussion evaluations per game.
Data from a recently completed study showed that older retired NFL players had an increased rate of neurocognitive decline compared to non-players. Interestingly, a history of concussion where consciousness was lost had the greatest effect on neurocognitive performance in older athletes. The NFL and NCAA continue to deal with legal claims surrounding concussions.
Internationally, Australian Rules footballers have recently brought legal action against the league for downplaying the risk of head injury and failing to have proper protocols in place to protect the players. The cost to the league could be as high as $2 million per player. The league recently reversed its stance and now accepts that CTE is caused in part by repetitive head trauma. In the past few years, concussions in elite rugby leagues have hit an all-time high since records kept. Over twenty-two (22) concussions were documented per one thousand (1000) hours of rugby play. In a significant move, the leagues have instituted a 12-day no-play clause if the player is diagnosed with a concussion.
“Given the reported incidences cited, Odyssey Health recognizes the urgent need to bring an effective pharmaceutical to market to treat the concussion epidemic. Not only are the therapeutic effects of the drug vital, but there is a need for a field-deliverable and brain-targeted approach to the drug delivery. Our intranasal delivery should optimize the success of the drug when given to our athletes,” commented Michael Redmond, CEO for Odyssey Health, Inc.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus on life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the Company’s website at www.odysseyhealthinc.com
We encourage our shareholders to visit our corporate social media accounts for updates:
https://twitter.com/OdysseyHealth1
https://www.facebook.com/odysseyhealthinc
https://www.linkedin.com/company/odysseyhealthinc
https://www.youtube.com/channel/UCsS--v0od_fYIBu2tvqmj9Q
About ONP-002
ONP-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, ONP-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that ONP-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, ONP-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. Our novel breath-propelled, intranasal brain-drug delivery device is designed with a novel drug dispensing system that creates an effective airflow for depositing concentrated drug deep into the nasal cavity and onto the olfactory region, this could allow for quick and direct diffusion into the brain..
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete clinical trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Inquiries:
Odyssey Health
Contact Details
Odyssey Health
